Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Immunocore Medical Information EU +00 800-744-51111
medinfo.eu@immunocore.com


Immunocore Medical Information 844-466-8661
medical.information@immunocore.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Back

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Recruiting

Open to: ALL

Age: 18.0 - N/A

Leeds Cambridge Birmingham London Middlesex Sutton

Medical Conditions

Melanoma

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The purpose of this study is to evaluate the efficacy and safety of tebentafusp-based regimens, including tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of care \[SoC\], best supportive care \[BSC\] on protocol survivor follow up) in patients with advanced non-ocular melanoma.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Dec 2022 Mar 2028

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Soluble gp100-specific T cell receptor with anti-CD3 scFV

Intervention Arm Group : Arm A: Tebentafusp Monotherapy;

Intervention Type : DRUG
Intervention Description : Soluble gp100-specific T cell receptor with anti-CD3 scFV in combination with pembrolizumab

Intervention Arm Group : Arm B: Tebentafusp + Pembrolizumab;

Intervention Type : DRUG
Intervention Description : Investigators choice of therapy

Intervention Arm Group : Arm C: Investigator's Choice;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Leeds General Infirmary
    Leeds
    LS1 3EX
  • Addenbrooke's Hospital
    Cambridge
    Cambridgeshire
    CB2 0QQ
  • Queen Elizabeth Hospital
    Birmingham
    West Midlands
    B15 2TH
  • Royal Marsden Hospital - Chelsea
    London
    SW3 6JJ
  • Mount Vernon Cancer Center
    Middlesex
    HA6 2RN
  • Royal Marsden Hospital - Sutton
    Sutton
    SM2 5PT

Immunocore Medical Information EU +00 800-744-51111
medinfo.eu@immunocore.com


Immunocore Medical Information 844-466-8661
medical.information@immunocore.com



The study is sponsored by Immunocore Ltd



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT05549297
Last updated 27 November 2024

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top